- Home
- TXO vs VIR Comparison
TXO vs VIR Comparison
Compare TXO & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXO
- VIR
- Stock Information
- Founded
- TXO 2012
- VIR 2016
- Country
- TXO United States
- VIR United States
- Employees
- TXO N/A
- VIR N/A
- Industry
- TXO Oil & Gas Production
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- TXO Energy
- VIR Health Care
- Exchange
- TXO Nasdaq
- VIR Nasdaq
- Market Cap
- TXO 665.3M
- VIR 724.1M
- IPO Year
- TXO 2023
- VIR 2019
- Fundamental
- Price
- TXO $16.92
- VIR $5.50
- Analyst Decision
- TXO
- VIR Strong Buy
- Analyst Count
- TXO 0
- VIR 7
- Target Price
- TXO N/A
- VIR $33.57
- AVG Volume (30 Days)
- TXO 85.8K
- VIR 1.4M
- Earning Date
- TXO 05-06-2025
- VIR 05-01-2025
- Dividend Yield
- TXO 14.23%
- VIR N/A
- EPS Growth
- TXO N/A
- VIR N/A
- EPS
- TXO 0.65
- VIR N/A
- Revenue
- TXO $282,810,000.00
- VIR $74,205,000.00
- Revenue This Year
- TXO $30.49
- VIR N/A
- Revenue Next Year
- TXO N/A
- VIR $17.69
- P/E Ratio
- TXO $26.03
- VIR N/A
- Revenue Growth
- TXO N/A
- VIR N/A
- 52 Week Low
- TXO $15.22
- VIR $4.95
- 52 Week High
- TXO $23.56
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- TXO 40.11
- VIR 35.61
- Support Level
- TXO $16.15
- VIR $5.32
- Resistance Level
- TXO $17.22
- VIR $5.73
- Average True Range (ATR)
- TXO 0.93
- VIR 0.45
- MACD
- TXO -0.10
- VIR 0.05
- Stochastic Oscillator
- TXO 31.41
- VIR 32.35
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.